143 related articles for article (PubMed ID: 11977554)
1. [The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection--a retrospective study].
Nakayama S; Matsubara N; Sakai T; Aso N
Gan To Kagaku Ryoho; 2002 Apr; 29(4):633-5. PubMed ID: 11977554
[No Abstract] [Full Text] [Related]
2. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
3. [Phlebitis after vinorelbine].
Sauter C; Margulies A; Pestalozzi B
Schweiz Med Wochenschr; 1998 Feb; 128(9):343. PubMed ID: 9544462
[No Abstract] [Full Text] [Related]
4. Vinorelbine and venous irritation: optimal parenteral administration.
de Lemos ML
J Oncol Pharm Pract; 2005 Jun; 11(2):79-81. PubMed ID: 16460608
[TBL] [Abstract][Full Text] [Related]
5. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
6. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y
Jpn J Clin Oncol; 2004 Apr; 34(4):206-9. PubMed ID: 15121757
[TBL] [Abstract][Full Text] [Related]
7. Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine.
Liebmann J; Friedman K
Am J Med; 1996 Dec; 101(6):658-9. PubMed ID: 9003116
[No Abstract] [Full Text] [Related]
8. [Consideration of preventive free-flowing IV infusion method for vinorelbine].
Suga Y; Hara Y; Hashimoto H; Nishigami J; Shimizu M; Akasaka H; Hayashi K; Yonejima M; Nakamura M; Inokuchi M; Kasahara K; Nishimura G; Miyamoto K
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1255-7. PubMed ID: 17687207
[TBL] [Abstract][Full Text] [Related]
9. Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1).
Crawford J; Chang AY; Gralla RJ; Souquet PJ; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):22-4. PubMed ID: 8610233
[No Abstract] [Full Text] [Related]
10. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F
Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine].
Cinieri S; Orlando L; Cocorocchio E; Munzone E; Catania C; Brunetti C; Rocca A; Martinelli G; Nolè F
Clin Ter; 1999; 150(3):225-9. PubMed ID: 10528436
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine--a clinical review.
Gregory RK; Smith IE
Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
[No Abstract] [Full Text] [Related]
18. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC.
Jensen LH; Osterlind K; Rytter C
Lung Cancer; 2008 Oct; 62(1):85-91. PubMed ID: 18372075
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer.
Mori K; Kamiyama Y; Kondo T; Kano Y; Tominaga K
Cancer Chemother Pharmacol; 2004 Feb; 53(2):129-32. PubMed ID: 14605861
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
